Related Experiment Video
Updated: Jun 29, 2026

Assays for Validating Histone Acetyltransferase Inhibitors
Published on: August 6, 2020
HDAC4 represses p21(WAF1/Cip1) expression in human cancer cells through a Sp1-dependent, p53-independent mechanism
D Mottet1, S Pirotte, V Lamour
1Metastasis Research Laboratory, GIGA-Cancer (Center for Experimental Cancer Research), University of Liège, Liège, Belgium.
Abstract:
Cancer cells have complex, unique characteristics that distinguish them from normal cells, such as increased growth rates and evasion of anti-proliferative signals. Global inhibition of class I and II histone deacetylases (HDACs) stops cancer cell proliferation in vitro and has proven effective against cancer in clinical trials, at least in part, through transcriptional reactivation of the p21(WAF1/Cip1)gene. The HDACs that regulate p21(WAF1/Cip1) are not fully identified. Using small interfering RNAs, we found that HDAC4 participates in the repression of p21(WAF1/Cip1) through Sp1/Sp3-, but not p53-binding sites. HDAC4 interacts with Sp1, binds and reduces histone H3 acetylation at the Sp1/Sp3 binding site-rich p21(WAF1/Cip1) proximal promoter, suggesting a key role for Sp1 in HDAC4-mediated repression of p21(WAF1/Cip1). Induction of p21(WAF1/Cip1) mediated by silencing of HDAC4 arrested cancer cell growth in vitro and inhibited tumor growth in an in vivo human glioblastoma model. Thus, HDAC4 could be a useful target for new anti-cancer therapies based on selective inhibition of specific HDACs.
Insights
Histone deacetylase 4 (HDAC4) represses the p21(WAF1/Cip1) gene in cancer cells. Silencing HDAC4 reactivates p21(WAF1/Cip1), halting cancer and glioblastoma growth, suggesting HDAC4 as a therapeutic target.
Area of Science:
- Molecular Biology
- Cancer Research
- Epigenetics
Background:
- Cancer cells exhibit uncontrolled proliferation and evade growth inhibition signals.
- Global inhibition of histone deacetylases (HDACs) shows anti-cancer effects, partly via p21(WAF1/Cip1) gene reactivation.
- Specific HDACs regulating p21(WAF1/Cip1) remain largely unidentified.
Purpose of the Study:
- To identify the specific HDACs involved in p21(WAF1/Cip1) gene repression.
- To investigate the role of HDAC4 in regulating p21(WAF1/Cip1) expression and its impact on cancer cell proliferation.
- To evaluate HDAC4 as a potential therapeutic target for cancer treatment.
Main Methods:
- Utilized small interfering RNAs (siRNAs) to silence HDAC4 expression.
- Analyzed p21(WAF1/Cip1) gene regulation through Sp1/Sp3 and p53 binding sites.
- Investigated HDAC4 interaction with Sp1 and its effect on histone acetylation at the p21(WAF1/Cip1) promoter.
- Assessed the impact of HDAC4 silencing on cancer cell growth in vitro and tumor growth in a human glioblastoma xenograft model.
Main Results:
- HDAC4 was found to repress p21(WAF1/Cip1) via Sp1/Sp3 binding sites, independent of p53.
- HDAC4 interacts with Sp1 and reduces histone H3 acetylation at the p21(WAF1/Cip1) promoter.
- Silencing HDAC4 led to p21(WAF1/Cip1) induction, inhibiting cancer cell proliferation in vitro.
- HDAC4 inhibition suppressed tumor growth in an in vivo human glioblastoma model.
Conclusions:
- HDAC4 plays a critical role in repressing the p21(WAF1/Cip1) gene in cancer.
- HDAC4-mediated repression of p21(WAF1/Cip1) involves interaction with Sp1.
- Targeting HDAC4 represents a promising strategy for novel anti-cancer therapies through selective HDAC inhibition.
Related Concept Videos
Abnormal Proliferation
Inhibition of Cdk Activity
Negative Regulator Molecules
Anaphase Promoting Complex
Separation of Sister Chromatids
At the onset of anaphase, separase, a proteolytic enzyme, is...
Hedgehog Signaling Pathway

